Moderna gains as Arbutus/ Genevant settlement removes major financial risk
Source: SeekingAlpha
2026-03-04 09:18:05 ET
More on Moderna, Arbutus Biopharma, etc.
- Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation Transcript
- Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Roivant Sciences Ltd. (ROIV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Moderna surges after hours on patent settlement with Arbutus and Genevant
- Pfizer-backed Priovant wins FDA priority review for lead asset
Read the full article on Seeking Alpha
For further details see:
Moderna gains as Arbutus/ Genevant settlement removes major financial risk
Roivant Sciences Ltd.
NASDAQ: ROIV
ROIV Trading
2.5% G/L:
$29.98 Last:
2,347,026 Volume:
$28.985 Open:
ROIV Latest News
March 04, 2026 11:42:41 pm
BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide
March 03, 2026 04:15:00 pm
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
March 03, 2026 04:15:00 pm
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
ROIV Stock Data
$19,574,426,097
449,460,314
0.77%
170
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
